|Last Update: 05/17/13 - 4:00 PM EDT|
|YTD Performance: 12.34%|
|Previous Close: $46.37|
|52 Week Range: $37.02 - $48.79|
|Oustanding Shares: 3,019,611,844|
|Market Cap: 140,019,401,206|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||6||6||9||10|
|Growth Rate (Year over Year)||-20.95%||-3.68%||-8.58%||8.33%|
Here are seven reasons why.
You can't get away from the need for good yield in an era of commodity inflation.
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.
Focusing on near-term drug stock earnings is the wrong move.
Showing signs of technical deterioration.
When Europe's tame and China's out of the news, they come back to our stocks.
TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.
Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.